How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.
You may also be interested in...
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.
Research published in JAMA shows that the pharmaceutical industry outpaces other industries in the S&P 500 on several measures of profitability.
HHS Secretary Azar says $1bn of the $2.5bn emergency supplemental funding request is for vaccine development.